GeneDx (US:WGS) Prnewswireยท2025-06-18 23:45Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Allegations - The investigation is prompted by a report from Grizzly Research, which claims that GeneDx is involved in widespread fraud, suggesting that the company's growth is artificially inflated through fraudulent schemes targeting Medicaid and Medicare [3]. - Following the publication of the report on February 5, 2025, GeneDx's stock experienced a decline of 6.7% [3]. Group 2: Class Action Details - Investors who purchased GeneDx securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].